TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 12 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 12 years of age.

Mobile site search icon.
Mobile navigation icon.

TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 12 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 12 years of age.

TAKHZYRO Side Effects

Any time you’re considering a new treatment, it’s important to understand the potential risks and benefits.

Camila, a real TAKHZYRO® (lanadelumab-flyo) patient, sitting with her husband Jorge.
Camila
Jorge
Camila
Jorge

Talk to your doctor about potential TAKHZYRO side effects

TAKHZYRO may cause serious side effects, including allergic reactions. Call your doctor or get emergency help right away if you have any of the following symptoms:

  • wheezing
  • difficulty breathing
  • chest tightness
  • fast heartbeat
  • faintness
  • rash
  • hives

The most common side effects of TAKHZYRO are:

  • injection site reactions
    (pain, redness, and bruising)
  • upper respiratory infections
  • headache
Camila, a real TAKHZYRO® patient, walking on a colorful path.

Camila

Real TAKHZYRO patient

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of TAKHZYRO.

For more information, ask your healthcare provider or pharmacist.

Most common side effects in the 6.5-month clinical study
TAKHZYRO
(84 people)*
Placebo
(41 people)
Injection site reactions
52%
34%
Pain
43%
29%
Redness
10%
2%
Bruising
7%
0%
Upper respiratory infection
29%
32%
Headache
21%
22%
Rash
7%
5%
Muscle pain
5%
0%
Dizziness
6%
0%
Diarrhea
5%
5%

*Included all people treated with TAKHZYRO (300 mg every 2 weeks, 300 mg every 4 weeks, or 150 mg every 4 weeks) in the clinical study.

The most common side effects (occurring in ≥10% of people) seen in the long-term, open-label study were injection site reactions (including pain, redness, and bruising), upper respiratory infections, headache, and diarrhea.

Most common side effects in the 2.5-year, long-term, open-label study
TAKHZYRO 300 mg every 2 weeks (212 people)
Injection site pain
47%
Viral upper respiratory tract infection
42%
Upper respiratory tract infection
26%
Headache
25%
Injection site redness
17%
Joint pain
13%
Injection site bruising
12%
Back pain
12%
Diarrhea
11%
Sinus infection
11%
Influenza
10%
Nausea
10%
Urinary tract infection
10%

Before you use TAKHZYRO, tell your healthcare provider about all of your medical conditions, including if you:

  • are pregnant or planning to become pregnant. It is not known if TAKHZYRO can harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if TAKHZYRO passes into your breastmilk. Talk to your healthcare provider about the best way to feed your baby while using TAKHZYRO.

Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, or herbal supplements.

Icon of pen.

The safety and efficacy of TAKHZYRO were studied in one of the longest preventive trials in hereditary angioedema (HAE).

See study info

What made you want to start TAKHZYRO?

View Transcript

JENNY: What made me want to start TAKHZYRO®? I love that the dosing schedule is every two weeks.

BOBBI: I was interested in trying TAKHZYRO because I heard that it could lessen the frequency of my attacks and also the severity of my attacks, and that was something that meant a lot to me.

KELLY: I like the fact that most people were able to inject within a minute or less.

LEXI: I was, you know, trying to find any treatment method that just allowed me to take my medicine less. I wanted a chance to just have to have fewer attacks, the opportunity to have fewer attacks, and to be able to take medicine less.

LEXI: And so, having both of those opportunities, I knew I needed to give it a try.

SEBASTIAN: What interested me about TAKHZYRO was that it was every two weeks and that it wasn't plasma-based. That was really important.

NARRATOR: TAKHZYRO (lanadelumab) is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 12 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 12 years of age. TAKHZYRO may cause serious side effects, including allergic reactions.

NARRATOR: Call your healthcare provider or get emergency help right away if you have any of the following symptoms: wheezing, difficulty breathing, chest tightness, fast heartbeat, faintness, rash, and/or hives. The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, and headache. These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to the FDA at 1-800-FDA-1088.

NARRATOR: TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed. Talk to your healthcare provider about TAKHZYRO, the only preventive HAE treatment you take as a subcutaneous injection just once every two weeks.